Specialty Pharmacy

The findings could lead to speed the development of an HIV vaccine.

Top news of the day from across the health care landscape.

Up to 50% of patients with HER2-positive breast cancer treated with targeted therapies develop brain metastases.

FDA approval of valbenazine (Ingrezza) for the iatrogenic movement disorder tardive dyskinesia shows impact of a well-executed development program.

The TZA test is faster, more cost-effective, and less labor-intensive than the current test for finding dormant HIV cells.

Initiating biologics before triple therapy increases costs and provides minimal incremental benefit.

An experimental drug reactivated an enzyme to elicit tumor suppression.

Switching from DMARDs to first-line biologics may not be the optimal treatment for RA.

GatherMS aims to fill the resource knowledge gap in the MS landscape.

Top news of the day from across the health care landscape.

Health care has historically been physician-patient focused, but pharmacists and patients are changing this trend.

Outcomes-based contracting may soon play a role in the service level agreements between a specialty pharmacy provider and a manufacturer.

RA patients can consume up to 14 alcoholic beverages per week without increasing the risk of liver damage, but rates increase with increasing levels of alcohol consumption.

Gilead plans to file for approval of novel HIV drug in the United States and Europe this year.

Patient with MS was previously treated for 3 years with natalizumab, a known trigger of progressive multifocal leukoencephalopathy.

Continuous low-dose cisplatin through an implantable device could be a therapeutic option in for patients with ovarian cancer.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses trends in specialty drug cost management.

Top news of the day from across the health care landscape.

Metastatic urothelial carcinoma drug among key approvals from May 2017.

Statins also found to play key role in preventing cardiovascular events.

Rheumatoid arthritis drug among key FDA drug approvals from last month.

Top news of the week in oncology and cancer drug development.

As chemotherapy resistance builds, cancer cells develop a new Achilles’ heel.

The Centers for Medicare & Medicaid Services seeks to improve accuracy of data reported from direct and indirect remuneration fees.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

HIV-positive individuals are twice as likely to die of smoking than the disease.

Immune checkpoint inhibitors have revolutioned cancer treatment, but not all patients respond to immunotherapy.

Biosimilar programs seeks to increase accessibility to expensive medications.